Melanoma Clinical Trial

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

Summary

The purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination treatment on blood pressure and blood vessel function.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or female, age 40 - 75 years old
Diagnosis of cancer
Receiving VEGF inhibitor, ICI, or combination (VEGF inhibitor + ICI or combination ICI) treatment, or not receiving any treatment.
Normal blood pressure or blood pressure treated to < 140/90 mm Hg with ≤2 antihypertensive medications

Exclusion Criteria:

Presence of peripheral artery disease
History of a heart attack within 1 year
History of a stroke within 1 year
Diabetes
Life expectancy < 3 months
Women who are pregnant
Women who are nursing

Study is for people with:

Melanoma

Estimated Enrollment:

2

Study ID:

NCT03709771

Recruitment Status:

Terminated

Sponsor:

Vanderbilt University Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

2

Study ID:

NCT03709771

Recruitment Status:

Terminated

Sponsor:


Vanderbilt University Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider